Profiel
Marc Le Bozec is the founder of BioProtein Technologies SA, founded in 1998.
Mr. Bozec is currently the Chief Executive Officer at OSE Immunotherapeutics SA since 2025 and an Independent Director at Nicox SA since 2024.
Formerly, Director at CYTOO SA from 2013 to 2015.
Education includes an undergraduate degree from École des Hautes Études Commerciales de Paris.
Actieve functies van Marc Bozec
| Bedrijven | Functie | Begin |
|---|---|---|
| NICOX SA | Directeur/Bestuurslid | 16-07-2024 |
| OSE IMMUNOTHERAPEUTICS | Algemeen Directeur | 02-10-2025 |
Eerdere bekende functies van Marc Bozec
| Bedrijven | Functie | Einde |
|---|---|---|
CYTOO SA
CYTOO SA Medical SpecialtiesHealth Technology Operates as a contract research organization which develops physiological cell-based assays | Directeur/Bestuurslid | 01-01-2015 |
BioProtein Technologies SA
BioProtein Technologies SA BiotechnologyHealth Technology Develops recombinant therapeutic proteins and vaccines | Oprichter | - |
Opleiding van Marc Bozec
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Nicox SA
Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
BioProtein Technologies SA
BioProtein Technologies SA BiotechnologyHealth Technology Develops recombinant therapeutic proteins and vaccines | Health Technology |
École des Hautes Études Commerciales de Paris
École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CYTOO SA
CYTOO SA Medical SpecialtiesHealth Technology Operates as a contract research organization which develops physiological cell-based assays | Health Technology |
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
















